Relmada Therapeutics, Inc. (NASDAQ: RLMD) is a clinical-stage biopharmaceutical company focused on developing novel treatments for central nervous system disorders, including major depressive disorder and neuropathic pain. Founded in 2007 and headquartered in New York, Relmada is advancing a pipeline of small-molecule therapeutics designed to address unmet medical needs through innovative mechanisms of action. The company’s lead asset, dextromethadone (REL-1017), is an N-methyl-D-aspartate receptor antagonist being evaluated for its potential to rapidly alleviate symptoms of depression and reduce neuropathic pain without the liabilities of opioids.
Relmada’s development strategy emphasizes late-stage proof-of-concept studies and strategic partnerships to accelerate clinical progress. In addition to REL-1017, the company is advancing preclinical candidates aimed at modulating glutamatergic signaling and other pathways implicated in mood and pain disorders. Relmada has completed multiple phase 2 trials for REL-1017 in major depressive disorder and is preparing for pivotal studies, while exploring expansion into oncology-related neuropathic pain and other indications. The company leverages a lean operating model, outsourcing many trial activities to contract research organizations to maintain agility and focus on critical decision points.
With clinical programs spanning North America and Europe, Relmada collaborates with key academic centers and regulatory authorities to design trials that meet global standards. Its international footprint allows the company to recruit diverse patient populations and accelerate enrollment, while ongoing discussions with potential commercial partners aim to ensure broad market access upon regulatory approval. Relmada also invests in biomarker and translational research to better understand disease mechanisms and optimize patient selection for its novel agents.
Relmada’s leadership team is led by Stephan T. Wolff, Ph.D., President and Chief Executive Officer, whose background includes senior roles in biotech R&D and corporate strategy. The executive team brings extensive experience in neuroscience drug development, regulatory affairs, and business development. Guided by a board of directors and a scientific advisory board comprised of experts in neurology and psychiatry, Relmada is committed to delivering safe and effective therapies that improve quality of life for patients with challenging CNS conditions.
AI Generated. May Contain Errors.
